Skip to main content
Log in

A phase I and pharmacokinetic study of intravenous vinzolidine

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast-1, melanoma-2, renal cancer-2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Takasugi BJ, Robertone AB, Salmon SE, Alberts DS: Fiveday schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors. Invest New Drugs 2: 387–390, 1984

    Google Scholar 

  2. Takasugi BJ, Salmon SE, Nelson RL, Young L, Liu RM: Antitumor activity of vinzolidine in the human tumor clonogenic assay and comparison with vinblastine. Invest New Drugs 2: 49–53, 1984

    Google Scholar 

  3. Takasugi BJ, Jones SE, Robertone AB: Phase II trial of vinzolidine, an oral vinca alkaloid in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Treat Rep 68: 1399–1401, 1984

    Google Scholar 

  4. Budman DR, Schulman P, Marks M, Vinciguerra V, Weiselberg L, Kreis W, Degnan TJ: Phase I trial of vinzolidine. Cancer Treat Rep 68: 979–982, 1984

    Google Scholar 

  5. Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J: Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. Cancer Chemother and Pharmacol 14: 12–14, 1985

    Google Scholar 

  6. Nelson R: Clinical pharmacology of vinzolidine, a new orally active vinca alkaloid derivative (Abstr). Proc Amer SocClin Oncol 1: 19, 1983

    Google Scholar 

  7. Sethi VS, Burton SS, Jackson DV: A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 4: 183–187, 1980

    Google Scholar 

  8. Weiner DL: NONLIN 84/PCNONLIN: Software for the statistical analysis of nonlinear models. Meth and Find Exp Clin Pharmacol 8: 625–628, 1986

    Google Scholar 

  9. Boxenbaun HG, Riegelman S, Elashoff RM: Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 2: 123–143, 1974

    Google Scholar 

  10. Bender RA, Chabner BH: Tubulin binding agents. In: Chabner BA (ed) Pharmacologic Principles of Cancer Treatment, W.B. Saunders, Philadelphia, 1982, pp 256–268

    Google Scholar 

  11. Nelson RL, Dyke RW, Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 7 [Suppl]: 17–24, 1980

    Google Scholar 

  12. Owellen RJ, Hartke CA, Hains FO: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597–2602, 1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Dr. Taylor is the recipient of a Clinical Oncology Career Development Award from the American Cancer Society.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, C.W., Salmon, S.E., Satterlee, W.G. et al. A phase I and pharmacokinetic study of intravenous vinzolidine. Invest New Drugs 8 (Suppl 1), S51–S57 (1990). https://doi.org/10.1007/BF00171984

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00171984

Key words

Navigation